View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 1, 2021

Viz.ai obtains CE mark for AI-based stroke care software

In a study, Viz LVO showed a sensitivity of 96% and specificity of 94% in detecting large vessel occlusions.

Viz.ai has received CE mark to market its artificial intelligence (AI)-driven stroke care software, Viz LVO, in the European Economic Area.

The intelligent care coordination system links a variety of care teams, synchronises care and prioritises patients using its software suite. The suite can coordinate stroke care, lower time to treatment and enhance patient outcomes, clinical data shows.

Viz LVO leverages AI to identify suspected large vessel occlusion (LVO) strokes on computed tomography angiography (CTA) images.

It then notifies on-call stroke experts about the patients who could be treated in a standalone or multi-hospital setting.

Viz.ai co-founder and CEO Chris Mansi said: “Minutes matter when you’re having a stroke, which is why Viz.ai is dedicated to reducing time to treatment and improving patient outcomes through improved care coordination.

“The CE mark allows us to bring our leading AI software to the EU, significantly expanding the number of patients we can help get access to life-saving therapy.”

In a large, real-world multi-centre study, Viz LVO demonstrated a median time-to-notification of five minutes and 45 seconds across all trial centres.

Furthermore, the software had a sensitivity of 96% and specificity of 94% in detecting LVOs in 2,544 patients from 139 hospitals while utilising scanners from different companies.

The company noted that quicker triage with Viz LVO facilitates the detection and treatment of more people who require thrombectomy, which enhances patient outcomes and lowers long-term disability risks.

Stroke is the second common cause of mortality and a major cause of disability in adults in the European Union (EU). Viz.ai noted that only about 1.9% of patients get potentially lifesaving, less invasive endovascular procedure to remove blood clots.

Viz.ai received a de novo clearance for Viz LVO from the US Food and Drug Administration (FDA ) in February 2018.

In July 2019, Medtronic agreed to distribute Viz.ai ’s software across US centres.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network